Could an emerging modality provide a viable alternative to gadolinium-based contrast agents (GBCAs) in this high-risk patient population?
Carl Bjartmar, Chief Medical Officer, Ascelia Pharma
Advertisement
Articles by Carl Bjartmar, Chief Medical Officer, Ascelia Pharma
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Breast Ultrasound Study: High Glandular Tissue Component May Double Recurrence Risk for Invasive Breast Cancer
2
CMS Reverses Decision and Issues New Outpatient CPT Code for Ultrasound-Based QTscan
3
Agfa Radiology to Introduce AI-Powered DR 100s Pro X-Ray Platform at RSNA
4
Could an Emerging NacBI-RADS System for mpMRI Bolster Assessment of NAC Response?
5